Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,200 GBX | -0.88% | +0.45% | +22.81% |
Mar. 26 | Dr Martens cut to 'sell'; BofA likes Tullow | AN |
Mar. 25 | Judges Scientific Chair Hambro sells GBP110,000 in shares | AN |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 46.77 and 41.04 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Industrial Machinery & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.81% | 933M | C- | ||
+12.96% | 84.57B | A- | ||
+16.38% | 68.85B | B | ||
+12.13% | 34.99B | B- | ||
+19.98% | 33.27B | A | ||
+12.78% | 28.93B | B- | ||
+3.33% | 26.78B | C+ | ||
+0.73% | 25.51B | B+ | ||
+13.59% | 24.82B | B+ | ||
+16.37% | 24.6B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JDG Stock
- Ratings Judges Scientific plc